Zusammenfassung
Kombinatorische Verfahren haben sich in den letzten Jahren als Alternative zum rationalen Design in der Wirkstoffforschung etabliert, insbesondere dann, wenn keine strukturelle Information zur Verfügung steht. Hier wird das Prinzip vorgestellt, dass originär von zwei Wissenschaftlern und einer Wissenschaftlerin entwickelt und 2018 mit dem Nobelpreis für Chemie ausgezeichnet wurde. Weiterhin wird die Anwendung im Bereich der monoklonalen Antikörper diskutiert.
Abstract
Combinatorial procedures have become established in recent years as alternatives to rational design in drug research, particularly when no structural information is available. This article presents the principle that was originally developed by three scientists and was honored with the Nobel Prize for Chemistry in 2018. Furthermore, the application in the field of monclonal antibodies is discussed.
Weiterführende Literatur
Arnold FH (1998) Design by directed evolution. Acc Chem Res 31:125–131
Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L (2012) Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol 12:615–622
Cantani A (2008) Pediatric allergy, asthma and immunology. Springer, Berlin, Heidelberg, S 1–219
Collins J (1997) Phage display. Ann Rev Comb Chem Mol Div 1:210–262
Cwirla S, Peters E, Bartett R, Dower W (1990) Peptides on phage: a vast library of peptides for identifying ligands. Proc Natl Acad Sci USA 87:6378–6382
Ecker DM, Jones SD, Levine HL (2015) The therapeutic monoclonal antibody market. mAbs 7:9–14
Giver L, Arnold FH (1998) Combinatorial protein design by in vitro recombination. Curr Opin Chem Biol 2:335–338
Gregoret LM, Sauer RT (1998) Tolerance of a protein helix to multiple alanine and valine substitutions. Fold Des 3:119–126
Harris JL, Craik CS (1998) Engineering enzyme specificity. Curr Opin Chem Biol 2:127–132
Hoffmüller U, Schneider-Mergener J (1998) In vitro evolution and selection of proteins: ribosome display for larger libraries. Angew Chem Int Ed 37:3241–3243
Hubner B, Haensler M, Hahn U (1999) Modification of ribonuclease T1 by random mutagenesis of the substrate binding segment. Biochemistry 38:1371–1376
Jermutus L, Ryabova LA, Plückthun A (1998) Recent advances in producing and selecting functional proteins by using cell-free translation. Curr Opin Biotechn 9:534–548
Jucovic M, Poteete AR (1998) Delineation of an evolutionary salvage pathway by compensatory mutations of a defective lysozyme. Prot Sci 7:2200–2209
Katz BA (1997) Structural and mechanistic determination of affinity and specificity of ligands discovered or engineered by phage display. Ann Rev Biophys Biomol Struct 26:27–45
Klein C, Schaefer W, Regula JT (2016) The use of CrossMAb technology for the generation of bi- and multispecific antibodies. mAbs 8:1010–1020
Kuchner O, Arnold FH (1997) Directed evolution of enzyme catalysts. Trends Biotechn 15:523–530
Kumar R, Parray HA, Shrivastava T, Sinha S, Luthra K (2019) Phage display antibody libraries: a robust approach for generation of recombinant human monoclonal antibodies. Int J Biol Macromol 135:907–918
Lowman HB (1997) Bacteriophage display and discovery of peptides leads for drug development. Ann Rev Biophys Biomol Struct 26:401–424
Macbeath G, Kast P, Hilvert D (1998) Exploring sequence constraints on an interhelical turn using in vivo selection for catalytic activity. Prot Sci 7:325–335
Sauer RT (1996) Protein folding from a combinatorial perspective. Fold Des 1:R27–R30
Scott J, Smith GP (1990) Searching for peptide ligands with an epitope library. Science 249:386–390
Sharma S, Tammela J, Wang X et al (2007) Characterization of a putative ovarian oncogene, elongation factor 1A, isolated by panning a synthetic phage display single-chainvariable fragment library with cultured human ovarian cancer cells. Clin Cancer Res 13(19):2007
Singh S, Kumar NK, Dwiwedi P, Charan J, Kaur R, Sidhu P, Chugh VK (2018) Monoclonal antibodies: a review. Curr Clin Pharmacol 13:85–99
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
A.G. Beck-Sickinger gibt an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von der Autorin keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
J. Mössner, Leipzig
A. Neubauer, Marburg
Rights and permissions
About this article
Cite this article
Beck-Sickinger, A.G. Gerichtete Evolution in der Wirkstoff- und Antikörperentwicklung. Internist 60, 1014–1020 (2019). https://doi.org/10.1007/s00108-019-00675-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-019-00675-1
Schlüsselwörter
- Nobelpreis für Chemie 2018
- Verfahren der kombinatorischen Chemie
- Monoklonale Antikörper
- Phagen-Display
- Molekularbiologie